NCT Number	Status	Phase	Condition/Disease	Description
Anti-aging
NCT02432287	Completed	IV	Aging	Evaluate the effect of metformin on gene expression profiles in muscle and adipose tissue of older adults by RNA-Seq
NCT04264897	Recruiting	III	Aging	Assess changes in mitochondrial function and remodeling in skeletal muscle biopsies from patients treated with or without metformin
NCT01765946	Completed	IV	Aging	Evaluate longevity-related gene expression, including SIRT1, p66Shc, p53 and mTOR, in PBMCs
Anti-DR
NCT02587741	Recruiting	I	DR	Evaluate the efficacy of metformin on DR in comparison with Lantus and NovoMix30
Anti-cancer
NCT04559308	Recruiting	II	Breast cancer (BC)	Ascertain the antitumor effect with neoadjuvant chemotherapy (e.g., paclitaxel and doxorubicin)
NCT04387630	Recruiting	II	Early BC	Evaluate the immunostimulatory effect on preoperative chemotherapy
NCT02028221	Active, not recruiting	II	BC	Investigate BC prevention and favorable changes in risk features, including breast density and hormone levels
NCT02488564	Completed	II	Operable and locally advanced HER-2-positive BC	Evaluate the antitumor effect of the combination of liposomal doxorubicin plus docetaxel, trastuzumab and metformin
NCT02437656	Completed	II	Locally advanced rectal cancer	Evaluate the antitumor effect of metformin with neoadjuvant radiochemotherapy
NCT01941953	Completed	II	Metastatic CRC	Evaluate the efficacy of metformin plus fluorouracil in patients refractory to oxaliplatin and irinotecan
NCT02614339	Recruiting	III	Non-DM stage II high-risk/stage III CRC	Determine the impact of additional metformin on CRC recurrence
NCT01620593	Completed	II	Advanced prostate cancer	Evaluate the inhibitory effect of metformin on castration-induced tumor growth mediated by hyperinsulinemia
NCT02640534	Active, not recruiting	II	Metastatic castration-resistant prostate cancer (mCRPC)	Determine the efficacy of metformin plus enzalutamide compared to enzalutamide alone in patients with mCRPC
NCT02360618	Unknown	II	Invasive bladder cancer	Determine the synergistic antitumor effect of metformin and simvastatin on aggressive cancer cells
NCT02115464	Terminated	II	Locally advanced NSCLC	Evaluate the influence of chemoradiotherapy plus metformin on progression-free survival
NCT02019979	Terminated	II	Stage IIIB/IV non-squamous NSCLC	Determine the effect of metformin combined with platinum-based chemotherapy in patients on a carbohydrate-restricted diet
NCT01205672	Completed	I	Endometrial cancer	Evaluate the efficacy of metformin in non-diabetic women with endometrial cancer and determine S6K expression after treatment
NCT01529593	Unknown	I	Advanced cancer	Evaluate the efficacy of metformin plus temsirolimus (both mTOR inhibitors) on tumor regression
NCT03889795	Recruiting	I	Advanced pancreatic cancer	Evaluate the response to and effects of C3 (simvastatin + digoxin + metformin) on disease progression
NCT02143050	Unknown	I/II	Metastatic melanoma	Assess the safety and efficacy of metformin + dabrafenib + trametinib in patients with stage IIIC/IV melanoma